Risk factors of long hospital stay for immunoglobulin A vasculitis: Single-center study

Pediatr Int. 2018 Oct;60(10):918-922. doi: 10.1111/ped.13685.

Abstract

Background: Immunoglobulin A (IgA) vasculitis is a common, systemic childhood disease that occasionally interferes with oral intake of food and necessitates hospitalization. In Japan, there are no reports on the length of hospitalization or factors related to long-term hospitalization in children with IgA vasculitis. In this study, we investigated the factors related to long-term hospitalization.

Methods: We reviewed the medical records of children aged ≤15 years with IgA vasculitis who were admitted to the National Center for Child Health and Development (Tokyo, Japan) between March 2008 and April 2017. We reviewed their gender, age, previous episodes, digestive symptoms, fever, laboratory data, urine analysis, ultrasound, and use of glucocorticoid on admission day. We compared the long-stay (≥10 days) group (L) and the short-stay (≤9 days) group (S) on logistic regression analysis.

Results: Of the 68 children included in the analysis, 34 were male, and the average age was 71.9 ± 26.4 months. The median period of hospitalization was 10.5 days (range, 0.5-75 days), and 36 children were allocated to group L. In the logistic regression model including age, gender, gastrointestinal (GI) bleeding, and use of glucocorticoid, male sex (OR: 4.2; 95%CI: 1.3-13.5) and GI bleeding (OR: 7.6; 95%CI: 1.4-41.5) were significantly associated with hospitalization ≥10 days.

Conclusions: In children with IgA vasculitis, male patients and those with GI bleeding were more likely to have a hospital stay ≥10 days.

Keywords: gastrointestinal bleeding; gender; glucocorticoid; hospitalization; immunoglobulin A vasculitis.

Publication types

  • Observational Study

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Immunoglobulin A*
  • Infant
  • Infant, Newborn
  • Length of Stay / statistics & numerical data*
  • Logistic Models
  • Male
  • Retrospective Studies
  • Risk Factors
  • Vasculitis / immunology
  • Vasculitis / therapy*

Substances

  • Immunoglobulin A